Fig. 4

Combined treatment with OA and EGFR-TKIs abrogates the cytotoxic effect of EGFR-TKIs in vivo a Flowchart of the in vivo experiments. b In vivo luciferase activity measured after the establishment of tumor in mice pretreated for four weeks with vehicle (PBS, NT), Gefitinib (5 mg/kg/day) or Gefitinib (5 mg/kg/day) + OA (5 mg/kg/day). Quantification of luminescence is represented as the radiance. c-d Tumor weights and Tumor growth curves for each group were obtained. p values were determined by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. Data represent the mean ± SD of three replicate determinations. e HE and IHC staining for KI67, c-Caspase3, p-EGFR and SCD1. Data represent the mean ± SD of three replicate determinations. p values were determined by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars denote the SD